Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevasemten PK study with Verapamil and Food
NCT06916897Phase 1Completed
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sevasemten in Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) (3 arms). Primary endpoint: Pharmacokinetic Parameters up to 46 days. Started Jan 2025; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06916897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916897.